News for Collegium Pharmaceutical, Inc. (COLL)

STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced that its management will participate in the followin

**media[630782]**

Collegium Pharmaceutical, ticker COLL, has embarked on an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, aiming to buy back $25 million worth

STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL), a leading, diversified biopharmaceutical company committed to impro

Collegium Pharmaceutical (COLL) has received a price target adjustment from Piper Sandler, with analyst David Amsellem reiterating a "Neutral" rating for the st

Piper Sandler has revised its price target for Collegium Pharmaceutical (COLL), raising it to $37 from the previous $36. This adjustment reflects slightly impro

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Collegium Pharmac

The following slide deck was published by Collegium Pharmaceutical, Inc.

Call Start: 16:30 January 1, 0000 5:05 PM ETCollegium Pharmaceutical, Inc.

On March 31, 2025, Pacer Advisors, Inc. (Trades, Portfolio) executed a substantial reduction in its holdings of Collegium Pharmaceutical Inc. (COLL). The firm d

On December 31, 2024, Pacer Advisors, Inc. (Trades, Portfolio) executed a significant transaction involving Collegium Pharmaceutical Inc (COLL), reducing its ho

”“ Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year ”“ ”“ Grew Jornay PM® Prescriptions by 24% Year-over-Year and Reporte

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Collegium Pharmaceutical Inc. The firm reduced its holdings

STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced that it will report first quarter 2025 financial r

**media[578269]**

On March 21, 2025, Scott Dreyer, Executive Vice President & Chief Commercial Officer at Collegium Pharmaceutical Inc (COLL), sold 20,808 shares of the company.

”“ Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board ”“

**media[568249]**

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. ( COLL) today announced it will have two poster presentations highlighting